R848 (Resiquimod) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-?, IL-6 and IFN-?. R848 is being developed for HCV infection treatment [1], as vaccine adjuvants [2], and as combined cancer immunotherapy agent [3]

R848 (Resiquimod) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-?, IL-6 and IFN-?. R848 is being developed for HCV infection treatment [1], as vaccine adjuvants [2], and as combined cancer immunotherapy agent [3]